Elokom ointment 1 mg/g 15g №1

Name:
Elokom. Release form Ointment. INN Momethasone. FTGglucocorticosteroid for local use. Composition 1 g of ointment contains 1 mg of mometasone furoate; excipients: hexylene glycol, purified water, phosphoric acid, propylene glycol stearate, white wax, white petrolatum.
Description:
international and chemical names: mometasone; 9,21-dichloro-17(2-furanylcarbonyl)oxy-110-hydroxy-1ba-methylpregna-1,4-diene-3,20-dione monohydrate; basic physical and chemical properties: white or almost white opaque ointment, without foreign inclusions; Pharmacological action Mometasone furoate is a synthetic corticosteroid with anti-inflammatory, antipruritic, vasoconstrictive action. Pharmacokinetics The degree of penetration of topical corticosteroids through the skin depends on many factors, including the composition of the drug and the integrity of the epidermal barrier. Inflammation and other processes occurring in the skin can lead to increased penetration of the drug through the skin. A study on the absorption of 3H-mometasone furoate radioactively labeled ointment through the skin was performed on adult male volunteers with intact skin. Based on the amount of the isotope excreted in the feces and urine, after an 8-hour application of the ointment (without an occlusive dressing), approximately 0.7% of the applied dose was subjected to systemic absorption. Indications for use Topical treatment of symptoms of inflammation and itching in corticosteroid-responsive skin conditions, including psoriasis and atopic dermatitis. Contraindications Elokom is contraindicated in patients with hypersensitivity to any component of the drug. As well as other glucocorticoids, Elokom is contraindicated in patients with acne vulgaris, rosacea, perioral dermatitis, perianal and genital itching, bacterial, viral (herpes, varicella ocna; herpes zoster) or fungal skin infections, patients with tuberculosis, syphilis, post-vaccination Pregnancy and lactation The safety of the use of local glucocorticosteroids in pregnant women has not been proven, therefore, the appointment of this group of drugs during pregnancy is justified only if the potential benefit to the woman outweighs the potential risk to the fetus. During pregnancy, drugs of this group should not be used in large doses or for a long time. When prescribing Elokom to a pregnant woman, glucocorticoids may cross the placenta and affect the fetus. It is not clear whether topical corticosteroids due to systemic absorption can lead to their appearance in mother’s milk. Decision on terminations; breast-feeding or drug withdrawal should be taken taking into account the need to use the drug in the mother: Method of application and dose Elocom is applied in a thin layer to the affected areas of the skin 1 time per day. The duration of treatment is determined by the severity, course of the disease and is determined individually. The use of topical corticosteroids in children and adults on the face should not exceed 5 days. Continuous use of the drug should not exceed 2-3 weeks. Side effects After using the drug Elocom, there were reports of the following local adverse reactions: paresthesia, itching, signs of skin atrophy, burning, folliculitis, acne, papules, pustules and telangiectasias (frequency – very rare). The following local adverse reactions have been reported with the use of other potent glucocorticoids, they are possible with the use of Elocom: skin irritation, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, striae, prickly heat (frequency – rare). Systemic adverse reactions may occur (see section “Peculiarities of use”) when applying the ointment to large surfaces of the skin for a long time, especially when using an occlusive dressing. All adverse events that have been reported with the appointment of systemic glucocorticoids, including inhibition of the function of the hypothalamic-pituitary system, can develop with the appointment of potent glucocorticoids, especially in infants and children (see section “Use in Pediatrics”). OverdoseSymptoms: excessive or prolonged use of local glucocorticosteroids can cause depression of the function of the pituitary-adrenal system, which can lead to the development of secondary adrenal insufficiency. Treatment. Appropriate symptomatic treatment is indicated. Acute symptoms of hypercortisolism are usually reversible. If necessary, correction of electrolyte imbalance is indicated. In case of long-term use, gradual withdrawal of corticosteroids is recommended. Application features Elokom is indicated for dermatological use only and is not intended for use in ophthalmology. If irritation or hypersensitivity is noted during the use of the drug, treatment should be discontinued and appropriate therapy instituted. If an infection develops, an appropriate antifungal or antibacterial agent should be used. If within a short time it is not possible to achieve a positive effect, the use of the drug should be discontinued until the signs of infection are eliminated. Any side effects of systemic glucocorticosteroids, including suppression of the function of the adrenal cortex, can also be observed with topical application of glucocorticosteroids, especially in young children. When using the drug on a large surface of the body or in high doses, it is recommended to periodically monitor the function of the adrenal glands. It should be used with extreme caution in patients with psoriasis, since topical application of glucocorticosteroids in psoriasis can be dangerous due to relapse of the disease with the development of tolerance, the risk of generalization of pustular psoriasis and the development of local or systemic toxicity due to impaired skin barrier function. Systemic absorption of glucocorticosteroids when applied topically will be higher if the treatment is carried out on extensive body surfaces or when using occlusive dressings. In such cases, as well as with prolonged use of the drug, precautions should be taken. As with all potent glucocorticoid-based drugs, the use of Elocom under occlusive dressings, for a long time, on large areas of the skin, as well as on the face (no more than 5 days) and skin folds (axillary and inguinal areas) should be avoided. . Avoid getting the drug into the eyes (including the eyelid area), wounds and mucous membranes. Glucocorticoids can change the appearance of some skin lesions, making the diagnosis difficult. Elocom contains propylene glycol, which may cause skin irritation. Application in pediatrics. In children, there may be more frequent manifestation of signs of depression of the hypothalamic-pituitary-adrenal system and Cushing’s syndrome under the influence of local corticosteroids than in adults, which is associated with a higher absorption of the drug through a greater ratio of skin surface area to body weight. In this regard, the use of topical corticosteroids in children should be limited to the minimum effective amount of the drug. Chronic corticosteroid therapy can lead to impaired growth and development in children. Elokom should not be applied to areas of the skin under diapers or waterproof panties, as in this case the drug gets under the occlusive dressing. There are limited data on the use of the drug for the treatment of children under 2 years of age. The use of Elok in children older than 2 years should not last more than 5 days. Influence on the ability to drive vehicles and other mechanisms Elok does not affect the ability to drive a car and work with moving mechanisms. Release form Tubes of 15 g No. 1 in a cardboard box. Storage conditionsKeep out of the reach of children at a temperature not exceeding 25°C. Shelf life 3 years. Terms of dispensing from pharmacies By prescription. Buy Elokom ointment 1 mg/g 15g №1 Price for Elokom ointment 1 mg/g 15g №1